Download PDF
Horm Metab Res 2022; 54(01): 25-32
DOI: 10.1055/a-1717-9332
Endocrine Care

Effects of Long-Acting Somatostatin Analogues on Lipid Metabolism in Patients with Newly Diagnosed Acromegaly: A Retrospective Study of 120 Cases

Xiao-qing Shao  ‡
1   Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China
,
Zheng-yuan Chen‡
2   Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China
3   Shanghai Pituitary Tumor Center, Shanghai, China
,
Meng Wang
1   Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China
,
Ye-ping Yang
1   Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China
,
Yi-fei Yu
1   Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China
3   Shanghai Pituitary Tumor Center, Shanghai, China
,
Wen-juan Liu
1   Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China
,
Yi Wang
1   Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China
3   Shanghai Pituitary Tumor Center, Shanghai, China
,
Fang-fang Zeng
1   Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China
,
Wei Gong
1   Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China
,
Hong-ying Ye
1   Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China
3   Shanghai Pituitary Tumor Center, Shanghai, China
,
Yong-fei Wang
2   Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China
3   Shanghai Pituitary Tumor Center, Shanghai, China
,
Yao Zhao
2   Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China
3   Shanghai Pituitary Tumor Center, Shanghai, China
,
Li Zhang
1   Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China
,
Zhao-yun Zhang
1   Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China
3   Shanghai Pituitary Tumor Center, Shanghai, China
,
Min He
1   Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China
3   Shanghai Pituitary Tumor Center, Shanghai, China
,
Yi-ming Li
1   Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China
3   Shanghai Pituitary Tumor Center, Shanghai, China
› Author Affiliations Funding Information This work was supported by the foundation of Shanghai Hospital Development Center (SHDC12018X04), Science and Technology Commission of Shanghai Municipality (18140901602 and 18140901600), the National Natural Science Foundation of China (No. 81770840, No. 81970716, No. 81400844 and No. 81800720) and National Project in promoting the diagnosis and treatment of major diseases by MDT.
› Further Information
Also available at
    Permissions and Reprints

Abstract

The short-term effects of long-acting somatostatin analogues (SSAs) on lipid profiles in patients with acromegaly are not well studied. We retrospectively analyzed the effects of SSAs on lipid profiles and associated cardiovascular risk factors in a cohort of 120 newly diagnosed acromegaly patients. In this study, 69 females and 51 males were included. These patients were treated with either octreotide LAR (OCT) or lanreotide SR (LAN) for 3 months. After SSAs treatment, both GH and IGF-1 significantly decreased (p<0.001). Triglyceride (TG), total to high-density lipoprotein cholesterol (HDL-C) ratio, and lipoprotein (a) [Lp(a)] levels were significantly decreased, while HDL-C levels were increased (p<0.05). The reduction of mean serum GH (GHm) was positively associated with the decrease of TG (r=0.305, p=0.001) and Lp(a) (r=0.257, p=0.005), as well as the increase of HDL-C (r=−0.355, p<0.001). The changes of lipid profiles were observed only in OCT group, but not in LAN group. In addition, systolic blood pressure (SBP) had significantly declined after SSAs treatment, with an average reduction of 4.4 mmHg (126.7±1.28 vs. 122.3±1.44 mmHg, p=0.003), while no change was observed regarding diastolic blood pressure (DBP) (p>0.05). Fasting insulin, fasting C-peptide, and HOMA-IR were significantly decreased after SSAs treatment. In conclusion, our current study revealed that short-term SSAs treatment improves lipid profiles and other cardiovascular risk factors in patients with acromegaly.

Key words

acromegaly - somatostatin analogues - lipid profiles - triglycerides


Publication History

Received: 11 May 2021

Accepted after revision: 30 November 2021

Article published online:
05 January 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Sherlock M, Ayuk J, Tomlinson JW. et al. Mortality in patients with pituitary disease. Endocr Rev 2010; 31: 301-342
    CrossrefPubMedGoogle Scholar
  • 2 Powlson AS, Gurnell M. Cardiovascular disease and sleep-disordered breathing in acromegaly. Neuroendocrinology 2016; 103: 75-85
    CrossrefPubMedGoogle Scholar
  • 3 Delaroudis SP, Efstathiadou ZA, Koukoulis GN. et al. Amelioration of cardiovascular risk factors with partial biochemical control of acromegaly. Clin Endocrinol (Oxf) 2008; 69: 279-284
    CrossrefPubMedGoogle Scholar
  • 4 Arosio M, Sartore G, Rossi CM. et al. LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Italian multicenter octreotide study group. Atherosclerosis 2000; 151: 551-557
    CrossrefPubMedGoogle Scholar
  • 5 Colao A, Pivonello R, Galderisi M. et al. Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J Clin Endocrinol Metab 2008; 93: 2639-2646
    CrossrefPubMedGoogle Scholar
  • 6 Giustina A, Chanson P, Bronstein MD. et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010; 95: 3141-3148
    CrossrefPubMedGoogle Scholar
  • 7 Mercado M, Ramírez-Rentería C. Metabolic complications of acromegaly. Front Horm Res 2018; 49: 20-28
    CrossrefPubMedGoogle Scholar
  • 8 Colao A, Auriemma RS, Galdiero M. et al. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab 2009; 94: 3746-3756
    CrossrefPubMedGoogle Scholar
  • 9 Auriemma RS, Grasso LFS, Galdiero M. et al. Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. Endocrine 2017; 55: 872-884
    CrossrefPubMedGoogle Scholar
  • 10 Briet C, Ilie MD, Kuhn E. et al. Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature. Endocrine 2019; 63: 348-360
    CrossrefPubMedGoogle Scholar
  • 11 Baldelli R, Durante C, D'Amico E. et al. Serum leptin levels in acromegalic patients before and during somatostatin analogs therapy. J Endocrinol Invest 2003; 26: 1219-1224
    CrossrefPubMedGoogle Scholar
  • 12 Colao A, Marzullo P, Lombardi G. Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. Eur J Endocrinol 2002; 146: 303-309
    CrossrefPubMedGoogle Scholar
  • 13 Cozzi R, Montini M, Attanasio R. et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006; 91: 1397-1403
    CrossrefPubMedGoogle Scholar
  • 14 Benito P, Calanas A, Galvez MA. et al. Effect of octreotide on plasma lipid metabolism in acromegaly. Ann Pharmacother 1994; 28: 1198
    CrossrefPubMedGoogle Scholar
  • 15 Attanasio R, Lanzi R, Losa M. et al. Effects of lanreotide autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study. Endocr Pract 2008; 14: 846-855
    CrossrefPubMedGoogle Scholar
  • 16 Annamalai AK, Webb A, Kandasamy N. et al. A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. J Clin Endocrinol Metab 2013; 98: 1040-1050
    CrossrefPubMedGoogle Scholar
  • 17 Tan KCB, Pang RWC, Tiu SC. et al. Effects of treatment with Sandostatin LAR on small dense LDL and remnant-like lipoproteins in patients with acromegaly. Clin Endocrinol (Oxf) 2003; 59: 558-564
    CrossrefPubMedGoogle Scholar
  • 18 Shen M, Wang M, He W. et al. Impact of long-acting somatostatin analogues on glucose metabolism in acromegaly: a hospital-based study. Int J Endocrinol 2018; 3015854
    PubMedGoogle Scholar
  • 19 Colao A, Ferone D, Marzullo P. et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004; 25: 102-152
    CrossrefPubMedGoogle Scholar
  • 20 Sesmilo G, Fairfield WP, Katznelson L. et al. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. J Clin Endocrinol Metab 2002; 87: 1692-1699
    CrossrefPubMedGoogle Scholar
  • 21 Smith JC, Lane H, Davies N. et al. The effects of depot long-acting somatostatin analog on central aortic pressure and arterial stiffness in acromegaly. J Clin Endocrinol Metab 2003; 88: 2556-2561
    CrossrefPubMedGoogle Scholar
  • 22 Topaloglu O, Sayki Arslan M, Turak O. et al. Three noninvasive methods in the evaluation of subclinical cardiovascular disease in patients with acromegaly: epicardial fat thickness, aortic stiffness and serum cell adhesion molecules. Clin Endocrinol (Oxf) 2014; 80: 726-734
    CrossrefPubMedGoogle Scholar
  • 23 Wolters TLC, van der Heijden C, van Leeuwen N. et al. Persistent inflammation and endothelial dysfunction in patients with treated acromegaly. Endocr Connect 2019; 8: 1553-1567
    CrossrefPubMedGoogle Scholar
  • 24 Berg C, Petersenn S, Lahner H. et al. Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. J Clin Endocrinol Metab 2010; 95: 3648-3656
    CrossrefPubMedGoogle Scholar
  • 25 Boero L, Manavela M, Gomez Rosso L. et al. Alterations in biomarkers of cardiovascular disease (CVD) in active acromegaly. Clin Endocrinol (Oxf) 2009; 70: 88-95
    CrossrefPubMedGoogle Scholar
  • 26 Boero L, Manavela M, Merono T. et al. GH levels and insulin sensitivity are differently associated with biomarkers of cardiovascular disease in active acromegaly. Clin Endocrinol (Oxf) 2012; 77: 579-585
    CrossrefPubMedGoogle Scholar
  • 27 Colao A, Spiezia S, Cerbone G. et al. Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. Clin Endocrinol (Oxf) 2001; 54: 515-524
    CrossrefPubMedGoogle Scholar
  • 28 Vilar L, Naves LA, Costa SS. et al. Increase of classic and nonclassic cardiovascular risk factors in patients with acromegaly. Endocr Pract 2007; 13: 363-372
    CrossrefPubMedGoogle Scholar
  • 29 Wildbrett J, Hanefeld M, Fucker K. et al. Anomalies of lipoprotein pattern and fibrinolysis in acromegalic patients: relation to growth hormone levels and insulin-like growth factor I. Exp Clin Endocrinol Diabetes 1997; 105: 331-335
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Potter BJ, Beauregard C, Serri O. Serum markers of cardiovascular risk in patients with acromegaly before and after six months of treatment with octreotide LAR. Pituitary 2008; 11: 49-53
    CrossrefPubMedGoogle Scholar
  • 31 Akgul E, Tokgozoglu SL, Erbas T. et al. Evaluation of the impact of treatment on endothelial function and cardiac performance in acromegaly. Echocardiography 2010; 27: 990-996
    CrossrefPubMedGoogle Scholar
  • 32 Olarescu NC, Heck A, Godang K. et al. The metabolic risk in patients newly diagnosed with acromegaly is related to fat distribution and circulating adipokines and improves after treatment. Neuroendocrinology 2016; 103: 197-206
    CrossrefPubMedGoogle Scholar
  • 33 Reid TJ, Jin Z, Shen W. et al. IGF-1 levels across the spectrum of normal to elevated in acromegaly: relationship to insulin sensitivity, markers of cardiovascular risk and body composition. Pituitary 2015; 18: 808-819
    CrossrefPubMedGoogle Scholar
  • 34 Verhelst J, Velkeniers B, Maiter D. et al. Active acromegaly is associated with decreased hs-CRP and NT-proBNP serum levels: insights from the Belgian registry of acromegaly. Eur J Endocrinol 2013; 168: 177-184
    CrossrefPubMedGoogle Scholar
  • 35 Cozzolino A, Feola T, Simonelli I. et al. Metabolic complications in acromegaly after neurosurgery: a meta-analysis. Eur J Endocrinol 2020; 183: 597-606
    CrossrefPubMedGoogle Scholar
  • 36 Feola T, Cozzolino A, Simonelli I. et al. Pegvisomant improves glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies. J Clin Endocrinol Metab 2019; 104: 2892-2902
    CrossrefPubMedGoogle Scholar
  • 37 Auriemma RS, Pivonello R, Galdiero M. et al. Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: a retrospective, comparative, head-to-head study. J Endocrinol Invest 2008; 31: 956-965
    CrossrefPubMedGoogle Scholar
  • 38 Cozzolino A, Feola T, Simonelli I. et al. Somatostatin analogs and glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies. J Clin Endocrinol Metab 2018; 103: 2089-2099
    CrossrefPubMedGoogle Scholar
  • 39 Colao A, Spinelli L, Cuocolo A. et al. Cardiovascular consequences of early-onset growth hormone excess. J Clin Endocrinol Metab 2002; 87: 3097-3104
    CrossrefPubMedGoogle Scholar
  • 40 Nishi Y. Nonclassical 3 beta-hydroxysteroid dehydrogenase deficiency in young girls with hirsutism and premature pubarche. Endocrinol Jpn 1990; 37: 763-767
    CrossrefPubMedGoogle Scholar
  • 41 Sardella C, Urbani C, Lombardi M. et al. The beneficial effect of acromegaly control on blood pressure values in normotensive patients. Clin Endocrinol (Oxf) 2014; 81: 573-581
    CrossrefPubMedGoogle Scholar
  • 42 Wexler TL, Durst R, McCarty D. et al. Growth hormone status predicts left ventricular mass in patients after cure of acromegaly. Growth Horm IGF Res 2010; 20: 333-337
    CrossrefPubMedGoogle Scholar
  • 43 Verhelst J, Velkeniers B, Maiter D. et al. Active acromegaly is associated with decreased hs-CRP and NT-proBNP serum levels: insights from the Belgian registry of acromegaly. Eur J Endocrinol 2013; 168: 177-184
    CrossrefPubMedGoogle Scholar
  • 44 Akutsu H, Kreutzer J, Wasmeier G. et al. Acromegaly per se does not increase the risk for coronary artery disease. Eur J Endocrinol 2010; 162: 879-886
    CrossrefPubMedGoogle Scholar
  • 45 Lombardi G, Colao A, Marzullo P. et al. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study. J Endocrinol Invest 2002; 25: 971-976
    CrossrefPubMedGoogle Scholar